Bristol-Myers Squibb and ANI Pharmaceuticals are both companies operating within the pharmaceuticals segment.
4 reports, 1 independent
Updated Aug 6
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb and ANI Pharmaceuticals are both companies operating within the pharmaceuticals segment.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Bristol-Myers Squibb and ANI Pharmaceuticals are companies in the pharmaceuticals segment.1 source
Bristol-Myers Squibb, Amneal Pharmaceuticals, and Merck were noted on August 4, 2025, as companies operating within the pharmaceuticals segment.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
ANI Pharmaceuticals (United States)
company in Baudette, United States
-
Merck
public company in Indonesia
Related events
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Bristol-Myers Squibb has taken ownership of Celgene's drug.
- Pfizer is based in New York and Bristol-Myers Squibb is based in Princeton, New Jersey.
Coverage
Newest first; wire copies grouped- StockStoryANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before the bell. Here’s what to look f
- StockStoryAmneal Earnings: What To Look For From AMRX Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings this Tuesday before the bell. Here’s what investors should know. Amn